Sarepta's exon-skipping therapies for DMD – Exondys 51, Vyondys 53 (golodirsen), and Amondys 45 (casimersen) – have been the main drivers of Sarepta's revenue growth in recent years ...

Golodirsen – an exon 53-skipping agent – is heading for an FDA verdict in the summer and if approved would be suitable for around 8% of DMD patients. One of the most common fatal genetic ...